Unknown

Dataset Information

Statin-associated regulation of hepatic PNPLA3 in patients without known liver disease.


ABSTRACT:

Background and objectives

Statins are used for metabolic dysfunction-associated steatotic liver disease (MASLD) (NAFLD) treatment, but their role in this context is unclear. Genetic variants of patatin-like phospholipase domain containing 3 (PNPLA3) are associated with MASLD susceptibility and statin treatment efficacy. Access to liver biopsies before established MASLD is limited, and statins and PNPLA3 in early liver steatosis are thus difficult to study.

Methods

Liver biopsies were collected from 261 patients without known liver disease at surgery and stratified based on statin use and criteria for the metabolic syndrome (MS). Genotypes and transcript levels were measured using Illumina and Affymetrix arrays, and metabolic and lipoprotein profiles by clinical assays. Stati

SUBMITTER: Ahmed O 

PROVIDER: S-EPMC11636427 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature